Mfd. by :- Cipla Ltd (Fulfilled By : Magicine Pharma)
Magicine Pharma is registered with the Government Of NCT, India, Ministry Of Health in Government of Delhi, India, registration number DL-RAJ-122372 and as a wholesale distributor, department file No. 44208.
Brand name - Hepcvir L
Generic name - Sofosbuvir/Ledipasvir
Manufacturer - Cipla Ltd.
Salt composition - Ledipasvir (90mg) + Sofosbuvir (400mg)
Storage - Store at room temperature (10-30°C)
Dosage form - Oral (tablet)
Strength - 90mg/400mg
Packaging - Bottle of 28 tablets
Gender - Unisex
Prescription required - Yes
Indication - used in the treatment of Chronic hepatitis C virus (HCV) infection
Hepcvir L (Sofosbuvir 400mg and Ledipasvir 90mg) is a combination of two antiviral medications, used in the treatment of chronic (long-lasting) hepatitis C virus (HCV) infection in adults. It is a fixed-dose combination of Ledipasvir and Sofosbuvir. Ledipasvir and Sofosbuvir are the direct-acting antiviral medications. It is an antiviral medicine that works to lower the multiplication of viruses in the body and eliminates the virus from the body over a period of time.
Ledipasvir is an inhibitor of the HCV NS5A protein, which is required for viral replication. Sofosbuvir is an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is required for viral replication. Sofosbuvir is a nucleotide prodrug, that undergoes intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203), which can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator.
Thorough QT studies have been conducted for Sofosbuvir/Ledipasvir. The effect of Ledipasvir 120 mg twice daily (2.67 times the maximum recommended dosage) for 10 days on QTc interval was calculated in a randomized, multiple-dose, placebo- and active-controlled (moxifloxacin 400 mg), three-period, crossover thorough QT trial in 59 healthy subjects. At the dose of 120 mg twice daily (2.67 times the maximum recommended dosage), Ledipasvir does not prolong QTc interval to any clinically relevant extent. The effect of Sofosbuvir 400 mg (maximum recommended dosage) and 1,200 mg (three times the maximum recommended dosage) on QTc interval was calculated in a randomized, single-dose, placebo- and active-controlled (moxifloxacin 400 mg), four-period, crossover thorough QT trial in 59 healthy subjects. At a dose three times the maximum recommended dose, Sofosbuvir does not prolong QTc to any clinically relevant extent.
The active ingredient of Hepcvir L is Sofosbuvir/Ledipasvir.
Hepcvir L (Sofosbuvir 400mg and Ledipasvir 90mg) is used in the treatment of Chronic hepatitis C virus (HCV) infection.
Headache
Nausea
Insomnia
Fever
Chills
Muscle pain
Cramps
Tiredness
Diarrhea
Fainting
Loss of appetite
Skin rash
Itching
Irritability
Take the dose exactly as your healthcare provider directs. Do not crush, break or chew the tablet.
Take the next scheduled dose if you miss a dose (if it is already the time for your next dose). Do not double the dose strength in order to catch up.
In case of overdose, make sure to seek immediate medical support.
Tell your healthcare provider about all the medications you already take and your medical history.
During pregnancy and breastfeeding, make sure to consult your healthcare provider, before the consumption of Hepcvir L.
In patients with liver or/and kidney disease, Hepcvir L should be administered with caution.
Avoid consuming alcohol.
Do not change the dose strength, unless your healthcare provider tells you.
Do not stop taking Hepcvir L tablet, unless your healthcare provider tells you.
A- Hepcvir L (Sofosbuvir 400mg and Ledipasvir 90mg) is a combination of two antiviral medications, used in the treatment of chronic (long-lasting) hepatitis C virus (HCV) infection in adults.
A- Take the dose exactly as your healthcare provider directs. Do not crush, break or chew the tablet.
A- It is available in the strength of 400mg+90mg.
A- Store at room temperature (10-30°C). Keep it away from direct light, moisture and heat.
A- No, Hepcvir L is not a habit forming medicine.
A- While consuming Hepcvir L, avoid the consumption of fatty or sugary food items.
A- If you feel unwell after the consumption of Hepcvir L tablet, avoid driving and operating heavy machines.
A- Avoid the consumption of alcohol.
A- Please ask your healthcare provider before consuming this tablet in liver disease.
A- It is advised to administer this tablet with utmost caution in patients with kidney disease.
A- During pregnancy, do not take any medicine without doctor’s prescription.
A- Hepcvir L is safe for use during breastfeeding, only if prescribed by the healthcare provider.
A- Drink plenty of water, to stay hydrated.
Reference
Sofosbuvir/Ledipasvir: Mechanism, Side effects, and dosage available at: https://reference.medscape.com/drug/harvoni-ledipasvir-sofosbuvir-999970, https://clinicalinfo.hiv.gov/en/drugs/ledipasvirsofosbuvir/patient, and https://www.medicines.org.uk/emc/files/pil.11849.pdf.
Fill the Form
Talk to Executive
Get Tracking
Get Medicines Delivered
